Table 1.

Patient characteristics and the effect of aspirin on all-cause mortality and cancer mortality in randomized trials of aspirin (with an initial treatment period ≥4 years)a

Placebo-controlled, double-blindYesYesNoYesYesYesYesYes
Patients (n)5,0852,4355,1393,7112,5392,0351,2763,350
Median duration of scheduled treatment (y)
Aspirin dose (mg/d)75300/1,20050065081/10075100100
OR (95% CI) for any cancer death0.83 (0.62–1.11)0.45 (0.25–0.82)0.79 (0.55–1.14)1.14 (0.56–2.35)0.80 (0.47–1.37)0.53 (0.25–1.15)0.80 (0.47–1.37)0.86 (0.63–1.17)
OR (95% CI) for any death1.06 (0.87–1.29)0.90 (0.70–1.14)0.88 (0.72–1.09)0.91 (0.77–1.08)0.88 (0.55–1.40)0.77 (0.57–1.04)0.92 (0.68–1.25)0.94 (0.76–1.17)

Abbreviations: AAAT, Aspirin for Asymptomatic Atherosclerosis Trial; BDT, British Doctor's Trial; ETDRS, Early Treatment Diabetic Retinopathy Study; JPAD, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; POPADAD, Prevention of Progression of Arterial Disease and Diabetes; SAPAT, Swedish Angina Pectoris Aspirin Trial; TPT, Thrombosis Prevention Trial; UK-TIA, UK-Transient Ischaemic Attack.

  • aRefer refs. 17, 18, 21–26.